Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 322Magnetic Resonance Spectroscopy 219Biopsy 186Nivolumab 50X-Rays 45Radiation 42Immunoglobulin G 42Disulfides 42Paclitaxel 40pembrolizumab 39Taxes 39Cyclophosphamide 39Cisplatin 39Platinum 371,2-diaminocyclohexaneplatinum II citrate 37Carboplatin 36Radiotherapy 33atezolizumab 30Doxorubicin 30olaparib 25Gemcitabine 25venetoclax 24Ipilimumab 24CTLA-4 Antigen 24Bevacizumab 24Prednisone 22Vincristine 21Phantoms, Imaging 21cabozantinib 20durvalumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glutamate Carboxypeptidase II × 30 days × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡